Welcome to our dedicated page for Allarity news (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity stock.
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company advancing personalized cancer therapies through its Drug Response Predictor (DRP®) platform. This page provides investors and industry professionals with timely updates on clinical trials, regulatory milestones, and strategic developments.
Access consolidated news on stenoparib’s progress in treating advanced ovarian cancer, DRP® companion diagnostic advancements, and partnership announcements. Our repository ensures efficient tracking of Allarity’s precision oncology innovations, from early-phase trial designs to late-stage data disclosures.
Content includes earnings reports, FDA communications, research collaborations, and scientific presentations. Each update is curated to highlight developments in patient selection methodologies and therapeutic efficacy without speculative commentary.
Bookmark this page for streamlined monitoring of Allarity’s contributions to targeted cancer treatment. Regularly updated to reflect the most current information available, this resource remains essential for understanding the company’s position in the evolving precision medicine landscape.
Allarity Therapeutics (NASDAQ: ALLR) has signed a new commercial agreement with an undisclosed EU-based biotech company for its DRP® platform technology. The agreement includes a non-exclusive global license for selected proprietary Allarity DRP® algorithms in breast cancer and laboratory services from Allarity's Medical Laboratory in Denmark.
The partnership involves advanced transcriptome analysis services to support precision oncology solutions in breast cancer, with committed purchases for laboratory services over the next year. The DRP® platform uses gene expression profiling to predict tumor responses to specific therapies. Allarity currently holds DRPs for over 100 drugs, including both investigational and approved medications.
Allarity Therapeutics (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, has appointed Jeff Ervin as its new Chief Financial Officer. Ervin, who brings nearly 20 years of executive leadership experience, succeeds Alexander Epshinsky. He previously served as Co-CFO at NYSE-listed DayDayCook and CEO of NASDAQ-listed IMAC Holdings.
Ervin holds an MBA from Vanderbilt University and will initially join Allarity in a half-time capacity, with potential for full-time employment based on company needs. The company is focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, as a personalized cancer treatment using its proprietary DRP® patient selection technology.
Allarity Therapeutics (NASDAQ: ALLR) has received a patent acceptance notice from IP Australia for its Stenoparib DRP® companion diagnostic. The acceptance covers 40 claims for the company's proprietary drug-specific Drug Response Predictor (DRP®) technology used in conjunction with stenoparib, their Phase 2 dual PARP and WNT pathway inhibitor for personalized cancer treatment.
The patent will be advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent should be granted within 20 working days. Allarity currently holds 18 granted patents for drug-specific DRPs, including eight in the United States, and has additional Stenoparib DRP® patent applications pending in the U.S., Canada, Japan, China, and India.
Allarity Therapeutics (NASDAQ: ALLR) has announced the dosing of the second patient in its new Phase 2 clinical trial of stenoparib, a dual PARP and WNT pathway inhibitor, for treating advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.
The trial builds upon previous Phase 2 data that showed durable clinical benefit and favorable tolerability with twice-daily dosing. The study aims to evaluate stenoparib as a potential novel, targeted treatment option for patients with limited alternatives. Additionally, the trial will advance Allarity's proprietary Drug Response Predictor (DRP®) companion diagnostic and further study stenoparib's unique WNT-modulating mechanism of action.
Allarity Therapeutics (NASDAQ: ALLR) has announced its participation in the upcoming Pharma Partnering Summit US, scheduled for May 14-15 in San Diego. CEO Thomas Jensen will present a company overview highlighting their key assets: stenoparib, a Phase 2 dual PARP and WNT pathway inhibitor, and their DRP® companion diagnostic platform. The event serves as a business development and licensing conference for biotech and pharmaceutical executives. Jensen will be available for one-on-one meetings with registered attendees during the summit.
Allarity Therapeutics (NASDAQ: ALLR) has announced the presentation of a new Drug Response Predictor (DRP®) for daratumumab at the 2025 AACR Annual Meeting. The novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab treatment.
The DRP® was developed by analyzing gene expression patterns correlated with daratumumab sensitivity, identifying 53 genes - 27 associated with sensitivity and 26 with resistance. Using data from the KYDAR trial, the DRP demonstrated ability to predict treatment outcomes and survival in multiple myeloma patients.
This marks Allarity's first DRP® developed for an antibody therapy, expanding beyond their previous small-molecule drug predictors. The company currently has stenoparib, a dual PARP and WNT pathway inhibitor, in Phase 2 development for ovarian cancer and small cell lung cancer.